Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026
Adaptive Biotechnologies (Nasdaq: ADPT) will report fourth quarter and full year 2025 financial results after market close on Thursday, February 5, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Adaptive Biotechnologies (Nasdaq: ADPT) will report fourth quarter and full year 2025 financial results after market close on Thursday, February 5, 2026. Management will host a conference call and webcast beginning at 1:30 p.m. PT / 4:30 p.m. ET. Live audio will be available on the company Investors website and the webcast will be archived for replay within 24 hours.
Investors can listen via the company website at www.adaptivebiotech.com and should check the Investors section for the live link and replay.
Details
News Market Reaction – ADPT
On Jan 23, the first trading day after this news, ADPT closed 2.68% below the previous close.
Data tracked by StockTitan Argus for the Jan 23 session.
Key Figures
- Earnings release date
- February 5, 2026
- Scheduled Q4 and FY2025 results announcement
- Conference call time PT
- 1:30 p.m. Pacific Time
- Start time for earnings call
- Conference call time ET
- 4:30 p.m. Eastern Time
- Start time for earnings call
- Current price
- $17.57
- Price prior to earnings-date announcement
- 24h price change
- -1.68%
- Move on the day of the announcement
- 52-week high
- $20.76
- Upper end of 52-week range
- 52-week low
- $6.255
- Lower end of 52-week range
- Market capitalization
- $2,728,126,910
- Equity value prior to earnings call
Historical Context
-
Preliminary Q4 and FY2025 revenue growth with strong MRD performance.
-
Announcement of presentation at 44th Annual J.P. Morgan Healthcare Conference.
-
Two Pfizer collaborations with RA milestones potentially totaling about $890M.
-
Jefferies fireside chat on MRD and clonoSEQ assay technology.
-
clonoSEQ MRD featured in 89 abstracts and 36 orals at ASH 2025.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the fourth quarter and full year 2025 after market close on Thursday, February 5, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Live audio of the webcast will be available on the “Investors” section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hours after the event.
About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations and FP&A
201-396-1687
investors@adaptivebiotech.com
ADAPTIVE MEDIA
Erica Jones, Associate Corporate Communications Director
206-279-2423
media@adaptivebiotech.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.